rewrite this title Exact Sciences: The Best Stock for Cancer Blood Testing? – Nanalyze

The world is divided in many ways these days, but we generally can all agree on at least one thing. Cancer sucks. Nearly 10 million people will die from some form of the disease this year, and there is about a 10% chance that you will meet your end thanks to the big C, according to all sorts of fun facts from the World Health Organization. 

We’ve been writing about technology to treat and prevent cancer for more than a decade, from startups developing liquid biopsy cancer tests to genetic testing. While treatments like immunotherapy have been game-changers for many, early detection is your best bet for long-term survival. For instance, studies have shown that screenings have averted about 25% of breast cancer deaths, which is why technologies like computer vision are helping with early detection of the disease. And while AI-powered cancer diagnostics is certainly an exciting field, most of our attention has been on a different market.

Massive Market Opportunity 

Earlier this year, we wrote about the massive cancer blood testing opportunity.The market basically breaks down into three segments, as we see it:

Personalized oncology: Analyze tumor DNA in the blood to guid